Vanguards of Health Care by Bloomberg Intelligence
Absci Leveraging Gen AI for Best-in-Class Antibodies
27 Feb 2025
“As US biotech companies, how do we continue to differentiate and create novel breakthrough assets? I think it’s leveraging AI,” said Sean McClain, founder and CEO of Absci. McClain and Christian Stegmann, senior vice president of drug creation, sit down with Bloomberg Intelligence analyst Andrew Galler in this episode of the Vanguards of Health Care podcast to discuss Absci’s generative AI platform and developing best-in-class biologics.See omnystudio.com/listener for privacy information.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other episodes from Vanguards of Health Care by Bloomberg Intelligence
Transcribed and ready to explore now
Aegis Ventures’ Blueprint for Building AI-Native Companies
04 Dec 2025
Vanguards of Health Care by Bloomberg Intelligence
Beta Bionics Does the Work to Reduce Insulin Pump Burden
20 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
Fosun Pharma’s Drive Beyond China
17 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
ARS Pharma’s Clinical Differentiation
13 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
Biolinq Introduces New Silicon Tech Opens Next Chapter of Glucose and Analyte Detection
06 Nov 2025
Vanguards of Health Care by Bloomberg Intelligence
Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody Drug Conjugates
27 Oct 2025
Vanguards of Health Care by Bloomberg Intelligence